NASDAQ:ZYXI

Zynex Competitors

$14.70
-0.81 (-5.22 %)
(As of 04/20/2021 12:59 PM ET)
Add
Compare
Today's Range
$14.64
Now: $14.70
$15.37
50-Day Range
$14.25
MA: $15.48
$17.57
52-Week Range
$12.30
Now: $14.70
$29.73
Volume4,441 shs
Average Volume603,329 shs
Market Capitalization$512.37 million
P/E Ratio44.55
Dividend YieldN/A
Beta0.6

Competitors

Zynex (NASDAQ:ZYXI) Vs. BLFS, NTUS, AXGN, TMDX, VRAY, and CUTR

Should you be buying ZYXI stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Zynex, including BioLife Solutions (BLFS), Natus Medical (NTUS), AxoGen (AXGN), TransMedics Group (TMDX), ViewRay (VRAY), and Cutera (CUTR).

BioLife Solutions (NASDAQ:BLFS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Insider & Institutional Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. Comparatively, 29.6% of Zynex shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by insiders. Comparatively, 50.5% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares BioLife Solutions and Zynex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioLife Solutions12.67%0.53%0.43%
Zynex18.08%50.67%35.56%

Volatility & Risk

BioLife Solutions has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for BioLife Solutions and Zynex, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioLife Solutions01902.90
Zynex02202.50

BioLife Solutions presently has a consensus target price of $46.6667, suggesting a potential upside of 49.05%. Zynex has a consensus target price of $21.6250, suggesting a potential upside of 46.81%. Given BioLife Solutions' stronger consensus rating and higher probable upside, equities analysts clearly believe BioLife Solutions is more favorable than Zynex.

Earnings and Valuation

This table compares BioLife Solutions and Zynex's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$27.37 million38.73$-1,660,000.00$0.08396.75
Zynex$45.47 million11.27$9.49 million$0.2852.50

Zynex has higher revenue and earnings than BioLife Solutions. Zynex is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

Zynex beats BioLife Solutions on 8 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Volatility & Risk

Natus Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Zynex has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Natus Medical and Zynex, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natus Medical01002.00
Zynex02202.50

Zynex has a consensus target price of $21.6250, suggesting a potential upside of 46.81%. Given Zynex's stronger consensus rating and higher possible upside, analysts clearly believe Zynex is more favorable than Natus Medical.

Profitability

This table compares Natus Medical and Zynex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natus Medical-4.33%3.87%2.50%
Zynex18.08%50.67%35.56%

Institutional and Insider Ownership

89.7% of Natus Medical shares are held by institutional investors. Comparatively, 29.6% of Zynex shares are held by institutional investors. 1.5% of Natus Medical shares are held by company insiders. Comparatively, 50.5% of Zynex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Natus Medical and Zynex's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natus Medical$495.52 million1.85$-15,670,000.00$1.2421.84
Zynex$45.47 million11.27$9.49 million$0.2852.50

Zynex has lower revenue, but higher earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Summary

Zynex beats Natus Medical on 10 of the 14 factors compared between the two stocks.

Zynex (NASDAQ:ZYXI) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Valuation & Earnings

This table compares Zynex and AxoGen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zynex$45.47 million11.27$9.49 million$0.2852.50
AxoGen$106.71 million6.93$-29,140,000.00($0.68)-26.68

Zynex has higher earnings, but lower revenue than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

29.6% of Zynex shares are owned by institutional investors. Comparatively, 78.4% of AxoGen shares are owned by institutional investors. 50.5% of Zynex shares are owned by insiders. Comparatively, 6.9% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Zynex and AxoGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zynex18.08%50.67%35.56%
AxoGen-22.98%-19.83%-14.88%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zynex and AxoGen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zynex02202.50
AxoGen02302.60

Zynex presently has a consensus target price of $21.6250, suggesting a potential upside of 46.81%. AxoGen has a consensus target price of $23.75, suggesting a potential upside of 33.88%. Given Zynex's higher probable upside, analysts clearly believe Zynex is more favorable than AxoGen.

Risk and Volatility

Zynex has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Summary

Zynex beats AxoGen on 9 of the 14 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares TransMedics Group and Zynex's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$23.60 million28.91$-33,550,000.00($2.36)-10.56
Zynex$45.47 million11.27$9.49 million$0.2852.50

Zynex has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 29.6% of Zynex shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Comparatively, 50.5% of Zynex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares TransMedics Group and Zynex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TransMedics Group-131.35%-38.95%-24.10%
Zynex18.08%50.67%35.56%

Risk & Volatility

TransMedics Group has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for TransMedics Group and Zynex, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TransMedics Group02302.60
Zynex02202.50

TransMedics Group presently has a consensus price target of $44.20, indicating a potential upside of 79.82%. Zynex has a consensus price target of $21.6250, indicating a potential upside of 46.81%. Given TransMedics Group's stronger consensus rating and higher probable upside, equities analysts clearly believe TransMedics Group is more favorable than Zynex.

Summary

Zynex beats TransMedics Group on 8 of the 14 factors compared between the two stocks.

ViewRay (NASDAQ:VRAY) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Earnings & Valuation

This table compares ViewRay and Zynex's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$87.78 million7.14$-120,200,000.00($1.18)-3.31
Zynex$45.47 million11.27$9.49 million$0.2852.50

Zynex has lower revenue, but higher earnings than ViewRay. ViewRay is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for ViewRay and Zynex, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ViewRay11502.57
Zynex02202.50

ViewRay currently has a consensus target price of $4.50, suggesting a potential upside of 13.92%. Zynex has a consensus target price of $21.6250, suggesting a potential upside of 46.81%. Given Zynex's higher probable upside, analysts plainly believe Zynex is more favorable than ViewRay.

Profitability

This table compares ViewRay and Zynex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ViewRay-166.74%-63.41%-36.34%
Zynex18.08%50.67%35.56%

Insider and Institutional Ownership

83.0% of ViewRay shares are held by institutional investors. Comparatively, 29.6% of Zynex shares are held by institutional investors. 15.5% of ViewRay shares are held by insiders. Comparatively, 50.5% of Zynex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

ViewRay has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Zynex has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Summary

Zynex beats ViewRay on 9 of the 14 factors compared between the two stocks.

Zynex (NASDAQ:ZYXI) and Cutera (NASDAQ:CUTR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares Zynex and Cutera's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zynex18.08%50.67%35.56%
Cutera-18.83%-61.21%-25.31%

Insider and Institutional Ownership

29.6% of Zynex shares are held by institutional investors. Comparatively, 87.8% of Cutera shares are held by institutional investors. 50.5% of Zynex shares are held by company insiders. Comparatively, 2.3% of Cutera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Zynex and Cutera, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zynex02202.50
Cutera01302.75

Zynex currently has a consensus price target of $21.6250, suggesting a potential upside of 46.81%. Cutera has a consensus price target of $30.6667, suggesting a potential upside of 10.55%. Given Zynex's higher probable upside, equities research analysts clearly believe Zynex is more favorable than Cutera.

Volatility and Risk

Zynex has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Cutera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Earnings and Valuation

This table compares Zynex and Cutera's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zynex$45.47 million11.27$9.49 million$0.2852.50
Cutera$181.71 million2.69$-12,350,000.00($0.88)-31.18

Zynex has higher earnings, but lower revenue than Cutera. Cutera is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Summary

Zynex beats Cutera on 9 of the 14 factors compared between the two stocks.


Zynex Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$31.74-3.1%$1.09 billion$27.37 million-43.48Insider Selling
Increase in Short Interest
NTUS
Natus Medical
1.1$27.08-3.7%$950.67 million$495.52 million-49.24
AxoGen logo
AXGN
AxoGen
1.7$18.14-1.9%$725.74 million$106.71 million-28.79News Coverage
TransMedics Group logo
TMDX
TransMedics Group
1.6$24.93-4.3%$711.89 million$23.60 million-17.81Increase in Short Interest
ViewRay logo
VRAY
ViewRay
1.5$3.90-6.9%$670.54 million$87.78 million-4.38News Coverage
Gap Up
Cutera logo
CUTR
Cutera
1.3$27.44-5.7%$515.89 million$181.71 million-15.16News Coverage
Edap Tms logo
EDAP
Edap Tms
1.3$8.28-2.8%$248.00 million$50.23 million-138.00Increase in Short Interest
Gap Down
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$7.14-2.2%$194.80 million$3.38 million-3.74Decrease in Short Interest
FONR
FONAR
1.1$17.64-1.5%$117.38 million$85.69 million16.64
IRIDEX logo
IRIX
IRIDEX
0.9$7.05-5.2%$115.17 million$43.45 million-12.82Gap Up
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.47-2.6%$113.17 millionN/A0.00
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.19-4.6%$95.26 million$10,000.00-1.19Analyst Downgrade
Gap Up
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.13-4.4%$94.07 millionN/A-1.49Analyst Downgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.76-5.4%$89.68 million$2.39 million-2.22Gap Down
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$17.11-1.1%$39.98 million$1.50 million-0.98
CHF Solutions logo
CHFS
CHF Solutions
1.7$4.98-6.4%$32.00 million$5.51 million-0.10Increase in Short Interest
News Coverage
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.47-3.6%$26.48 million$6.57 million-0.01
Star Equity logo
STRR
Star Equity
0.1$2.75-3.3%$13.09 million$114.18 million-0.88
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.